Autopsy report · NCT00723411

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)

“The primary endpoint at 15 months was not met.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 1 month before it stopped.
• 334 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Diamyd Therapeutics AB

Sponsor type

Industry

Conditions

Type 1 Diabetes Mellitus

Interventions

rhGAD65; rhGAD65; Placebo

Participants

334

Sites

70

Countries

Finland, France, Germany, Italy, Netherlands, Slovenia, Spain, Sweden, United Kingdom

Trials that died the same way

• OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
  “The primary endpoint was not achieved in the study.” (73% match in meaning)
• A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
  “The study did not meet the primary endpoint.” (72% match in meaning)
• Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
  “IA did not meet the prespecified primary endpoint.” (69% match in meaning)
• PleuraSeal Pivotal Study (US)
  “Interim analysis results were not supportive of primary endpoint” (67% match in meaning)
• Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
  “The study did not meet endpoint.” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.